A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or … (NCT06295692) | Clinical Trial Compass
Active — Not RecruitingPhase 3
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Japan19 participantsStarted 2024-02-09
Plain-language summary
The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
Who can participate
Age range12 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* The study participant has a diagnosis of generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP) at screening. For GPP, a diagnosis must be classified based on the criteria for diagnosis of GPP by the Japanese Dermatological Association (JDA); for EP, has a history of plaque-type psoriasis. In addition, has an involved body surface area (BSA) of lesion greater than or equal to (\>=) 80 percent (%) at baseline
* Candidate for phototherapy or systemic treatment for psoriasis (either naive or history of previous treatment)
* A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta-human chorionic gonadotropin \[beta-hCG\]) at screening and have a negative urine pregnancy test at Week 0 prior to administration of study intervention
* A male participant must agree not to plan to father a child while enrolled in this study or within 90 days after the last dose of study intervention
* A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after receiving the last dose of study intervention
Exclusion Criteria:
* The study participant has a total score of JDA severity index for GPP \>=14 at baseline if participants have a diagnosis of GPP
* The study participant has a differential diagnosis of the erythroderma (for example, erythroderma caused by lymphoma or drug eruption) other than EP
* The study participant has a histo…
What they're measuring
1
Percentage of Participants With Generalized Pustular Psoriasis (GPP) Who Experienced Treatment Success at Week 16
Timeframe: Week 16
2
Percentage of Participants With Erythrodermic Psoriasis (EP) Who Experience Treatment Success at Week 16